Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — For adults with type 2 diabetes and chronic kidney disease, a novel nonsteroidal ...

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...

For patients with musculoskeletal symptoms whose symptoms are not controlled by nonpharmacological approaches, pharmacological treatments should then be considered. When choosing any medication, both ...

Steroidal MRAs particularly benefit patients on dialysis, whereas nonsteroidal MRAs help treat patients with nondialysis-dependent CKD. Steroidal mineralocorticoid receptor antagonists (MRAs) reduce ...

The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease. Nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs) reduce the risk of ...

Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events ...

Panelists discuss how mineralocorticoid receptor antagonists (MRAs) remain underutilized despite being foundational therapy for heart failure with reduced ejection fraction due to clinician fears of ...

Credit: Italfarmaco. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 EPIDYS study. Duvyzat is the first nonsteroidal treatment approved for patients with ...

To date, ankylosing spondylitis (AS) has been treated with nonsteroidal anti-inflammatory drugs (NSAIDs), whilst maintaining a conservative dose regimen because of known gastrointestinal side effects.